ANALYSIS OF THE PHARMACEUTICAL MARKET OF HEPATOPROTECTIVE MEDICINES IN THE REPUBLIC OF KAZAKHSTAN

Adam Kazybek, Meruyert I. Tleubayeva

2024

Closed access Metadata (CSL-JSON)
DOI 10.53511/pharmkaz.2024.53.23.040
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

In accordance with the data of the State Register of Medicines of the Republic of Kazakhstan for 2023, the range of registered hepatoprotectors was analyzed. A comprehensive analysis of medicines registered in the state register by trade name, place of manufacture, country of origin, dosage form was carried out. According to the data of the State Register of Medicines of the Republic of Kazakhstan, 7544 medicines have been registered in the pharmaceutical market of the Republic of Kazakhstan. Among them, hepatoprotective drugs are represented under 78 trade names (CA), of which 6 (8%) are accounted for by domestic manufacturers.